Novo Nordisk Partners With Metaphore Biotechnologies on New Obesity Drugs
By Helena Smolak
Ozempic maker Novo Nordisk signed a research collaboration with U.S. biotech company Metaphore Biotechnologies to develop up to two advanced obesity treatments, which could cost the company up to $600 million.
Metaphore Biotechnologies said on Thursday that the Danish drug company, which makes weight-loss drugs Ozempic and Wegovy, will use Metaphore's tech platform, which combines machine learning with molecular mimicry, to develop the treatments.
This is the third research and development deal with Metaphore Biotechnologies' parent company Flagship Pioneering.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
May 09, 2024 10:30 ET (14:30 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations